The White House has put a price tag on lower Medicaid drug costs: $64.3 billion over ten years. Every dollar of it is a government budget figure. President Donald Trump announced the plan September 18, and the numbers are projections from the Council of Economic Advisers, the president’s in-house economists.
The fact sheet says most-favored-nation pricing, which ties what American buyers pay to the lowest price a company gives a comparable country, will reach all 50 state Medicaid programs.
Budget savings are not pharmacy savings
Readers asking whether this lowers their own prescription bills should look at who gets the money. The fact sheet says participating makers “will provide State Medicaid programs with rebates.” A rebate is a payment from the company to the state program, after the drug is sold.
That is a different thing from a lower price at the register. The fact sheet does not say any patient’s copay changes, and it does not mention Medicare drug plans in this section. The savings it counts belong to taxpayers, federal and state.
What changed this year: Social Security and Medicare change every year, and nobody sends you a memo. The Retirement Money Brief breaks down what changed and what to do. Bonus when you subscribe: our Prescription Coverage & Pharmacy Checklist.
Get the Brief and the prescription checklist →
We may earn a commission from links on this page.
Washington’s share and the states’ share
The Council of Economic Advisers puts the federal share at $36.6 billion and the state share at $27.6 billion. Together the two parts come to $64.2 billion on the page’s own numbers, against the $64.3 billion headline figure. The White House has not explained the $100 million gap.
Medicaid is paid for jointly, which is why both levels of government appear in the estimate. States run the programs and pay a share of the drug bill. The federal government pays the rest. A state with a large Medicaid population would collect more in rebates than a small one, though the fact sheet gives no state-by-state breakdown.
Spread evenly, $64.3 billion over ten years works out to about $6.4 billion a year. Savings rarely arrive that way. The fact sheet gives no start date, so the ten-year window is not tied to a calendar, and the sheet does not say how many years of the decade the rebates would actually run.
The White House’s case rests on a price gap. The fact sheet says American patients have paid “up to three times more” than patients in other developed countries for the same medicines. Closing part of that gap in Medicaid, the sheet argues, is where the savings come from.
How the rebates are supposed to work
The vehicle is the GENEROUS model from the Centers for Medicare & Medicaid Services. A Mercer Government summary says it lets the agency negotiate supplemental rebate agreements with manufacturers, on top of the rebates Medicaid already collects.
Mercer’s summary also says a state has to sign a participation agreement with the agency and run each rebate agreement across both fee-for-service and managed care enrollees. That can require a state plan amendment or new managed care contracts, steps that take time. The fact sheet, meanwhile, states no start date for the Medicaid benefit.
Mercer lays out the calendar the model followed. Manufacturers had until March 31, 2026 to apply, and talks between the agency and the companies over key terms ended June 30. Each company had to have a signed participation agreement and at least one rebate offer by that date.
The model also allows retroactive rebates for programs with qualifying use. A state cannot combine one of the model’s rebate agreements with a separate deal on the same drug, but it may still use other channels, such as multi-state purchasing pools. How much of the $64.3 billion is new money, and how much would have come through those older routes, is not broken out.
The $600 billion claim around it
The Medicaid number sits inside a larger one. The White House credits the same economists with an estimate of $600 billion in savings from all of its most-favored-nation deals over the next decade. By that math, the Medicaid piece is about a tenth of the total.
Neither number is a measured result. Both are forecasts, and the fact sheet publishes no formula, drug list or rebate rate that would let an outside reader redo them.
Drug bill relief that is already running
Medicare’s Extra Help program is operating now for people with limited income. Medicare.gov says that in 2027 it carries a $0 plan premium and $0 deductible. Generics cost up to $5.80 and brand-name drugs up to $14.40 at participating pharmacies. After total drug costs reach $2,400, covered drugs cost $0.
People with full Medicaid, a Medicare Savings Program or Supplemental Security Income get Extra Help automatically. Everyone else applies through the Social Security Administration.
Part of that help can arrive by phone. The Medicare.gov page lists a temporary-coverage line, called LI NET, at 1-800-783-1307 for people who qualify for Extra Help but are not yet in a drug plan. It runs 8 a.m. to 7 p.m. Eastern. People can reapply for Extra Help at any time if their income or savings change.
Does a $64.3 billion forecast change what you pay for prescriptions?
For a reader on Medicare or a limited income, the number that counts is the one on the pharmacy receipt. A budget projection with no start date does not lower it, and a missed application for drug-cost help can cost a full year of higher bills.
The Medicare Cost & Coverage Protection Kit includes 51 state Medicare cost-help packs, so the state programs that trim drug bills are laid out for your state. It also covers the Part D out-of-pocket cap, with a step-by-step section titled Get Help Paying.
Get your state’s drug-bill help pack and the Part D cap in one kit →
More Financial Reading
- The New $6,000 Senior Deduction and 14 More Tax Moves for Retirees
- 21 Ways to Stretch a $2,087 Social Security Check
- 15 Ways Out of 22% Credit Card Interest
This article was produced with the assistance of AI and reviewed by the editorial team.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
